4‐amino‐6‐alkyloxy‐2‐alkylthiopyrimidine derivatives as novel non‐nucleoside agonists for the adenosine A1 receptor

Three 4‐amino‐6‐alkyloxy‐2‐alkylthiopyrimidine derivatives (4–6) were investigated as potential non‐nucleoside agonists at human adenosine receptors (ARs). When tested in competition binding experiments, these compounds exhibited low micromolar affinity (Ki values comprised between 1.2 and 1.9 μm) for the A1 AR and no appreciable affinity for the A2A and A3 ARs. Evaluation of their efficacy profiles by measurement of intracellular cAMP levels revealed that 4 and 5 behave as non‐nucleoside agonists of the A1 AR with EC50 values of 0.47 and 0.87 μm, respectively. No clear concentration‐response curves could be instead obtained for 6, probably because this compound modulates one or more additional targets, thus masking the putative effects exerted by its activation of A1 AR. The three compounds were not able to modulate A2B AR‐mediated cAMP accumulation induced by the non‐selective AR agonist NECA, thus demonstrating no affinity toward this receptor.

[1]  B. Cosimelli,et al.  Synthesis and biological evaluation of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines as new inhibitors of the Wnt/β-catenin signaling. , 2014, European journal of medicinal chemistry.

[2]  G. V. van Westen,et al.  A Novel Nonribose Agonist, LUF5834, Engages Residues That Are Distinct from Those of Adenosine-Like Ligands to Activate the Adenosine A2a Receptor , 2011, Molecular Pharmacology.

[3]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[4]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[5]  A. Iskandrian,et al.  Regadenoson: a new myocardial stress agent. , 2009, Journal of the American College of Cardiology.

[6]  F. Sanz,et al.  Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines. , 2008, Bioorganic & medicinal chemistry.

[7]  E. Novellino,et al.  Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. , 2008, Journal of medicinal chemistry.

[8]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[9]  A. IJzerman,et al.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist‐specific G protein activation , 2004, British journal of pharmacology.

[10]  A. IJzerman,et al.  New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.

[11]  B. Fredholm,et al.  Signalling from adenosine receptors to mitogen-activated protein kinases. , 2003, Cellular signalling.

[12]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[13]  Duane D. Miller,et al.  Isothiocyanatobenzyl imidazoline is an alkylating agent for I2-imidazoline binding sites in rat and rabbit tissues , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  J. Cohn,et al.  Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunction. , 1996, Circulation.

[15]  B. Fredholm,et al.  A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. , 1990, Analytical biochemistry.